BELLUS Health Inc (TSE:BLU) Director Franklin Milan Berger purchased 50,000 shares of the business’s stock in a transaction on Thursday, June 20th. The stock was acquired at an average price of C$2.70 per share, for a total transaction of C$134,925.00. Following the completion of the purchase, the director now owns 1,502,108 shares of the company’s stock, valued at C$4,053,438.44.
BELLUS Health stock opened at C$2.52 on Thursday. BELLUS Health Inc has a 1-year low of C$0.51 and a 1-year high of C$3.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 13.65 and a current ratio of 13.87. The firm has a market capitalization of $418.59 million and a PE ratio of -27.39. The company has a fifty day simple moving average of C$1.72.
BELLUS Health (TSE:BLU) last posted its quarterly earnings results on Wednesday, May 8th. The company reported C($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of C($0.02) by C($0.01). The business had revenue of C$0.01 million during the quarter, compared to the consensus estimate of C$0.01 million. As a group, analysts anticipate that BELLUS Health Inc will post -0.08 earnings per share for the current year.
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Recommended Story: Back-End Load
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.